Boston Scientific Appoints Lucia Luce Quinn, Executive Vice President of Human Resources
(June 1, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that Lucia Luce Quinn has been appointed Executive Vice President of Human Resources. She will be responsible for Company-wide human resources efforts, supporting all Boston Scientific businesses, regions and functions, as well as corporate recruiting, compensation, benefits, policies and training. She will report to Jim Tobin, President and Chief Executive Officer, and she will serve on the Company's Executive Committee.

"Lucia brings a wealth of insight and experience to our team, acquired from leadership positions in health care, technology and manufacturing," said Tobin. "She will apply her business perspective and operations knowledge to our human resources strategy as we continue to attract, develop and retain the people who will help shape Boston Scientific's future."

Prior to joining Boston Scientific's senior management team in January, she served as Senior Vice President of Quest Diagnostics. At Quest, she was responsible for investment strategy, acquisitions, product development and key customer contracts for a portfolio of businesses with approximately $1 billion in revenue. Prior to Quest, she was Vice President of Corporate Strategic Marketing at Honeywell and held executive positions in operations, strategy, marketing and brand management for Digital Equipment Corporation.

She is currently Chairman of the Board of Trustees at Simmons College in Boston, an Overseer at Boston's Museum of Science and a member of the Committee of 200, a professional organization of women entrepreneurs and corporate leaders.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.